Literature DB >> 27816427

Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy.

Neal J Weinreb1, Deborah S Barbouth2, Robert E Lee3.   

Abstract

Treatment for type 1 Gaucher disease (GD1) decreases morbidity from hematological cytopenias, hepatosplenomegaly and bone complications. Consequently, untreated symptomatic patients for study of late outcomes are hard to find. We identified 184 untreated GD1 patients (67.4% Ashkenazi; splenectomy 51.1%) who died between 1950 and 2010. Here, we report confirmed causes of death for these patients compared with the overall US population. Median age of death 66years (2-97years); causes of death (COD) with a high proportional mortality rate (PMR) included malignancies (PMR 1.57), suicide/drug overdose (PMR 3.86), liver disease (PMR 4.76) and septicemia (PMR 9.22). PMRs for CNS/gastrointestinal bleeding, pulmonary hypertension, post-splenectomy complications and Parkinsonism were also increased. PMR for heart disease (0.33) was significantly decreased. Average age at death was normal for heart disease, septicemia, suicide, and malignancies but younger for liver disease and Parkinsonism. COD more prevalent in splenectomy patients included liver disease, septicemia, pulmonary hypertension and GI bleeding. With timely diagnosis, improved risk assessment and obsolescence of splenectomy, GD1-associated malignancies, liver disease, septicemia, pulmonary hypertension, suicide and drug dependency may decrease with early institution of appropriate treatment. Our population of untreated patients is a valuable historical control for studies of the effect of GD1 treatment on premature mortality.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Causes of death; Gaucher disease; Proportional mortality; Splenectomy; Untreated patients

Mesh:

Year:  2016        PMID: 27816427     DOI: 10.1016/j.bcmd.2016.10.002

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

Review 1.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

2.  Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Authors:  Pramod K Mistry; Julie L Batista; Hans C Andersson; Manisha Balwani; Thomas Andrew Burrow; Joel Charrow; Paige Kaplan; Aneal Khan; Priya S Kishnani; Edwin H Kolodny; Barry Rosenbloom; C Ronald Scott; Neal Weinreb
Journal:  Am J Hematol       Date:  2017-07-07       Impact factor: 10.047

Review 3.  Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Authors:  Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu
Journal:  Insights Imaging       Date:  2019-07-10

4.  Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease.

Authors:  Tama Dinur; Ari Zimran; Michal Becker-Cohen; David Arkadir; Claudia Cozma; Marina Hovakimyan; Sebastian Oppermann; Laura Demuth; Arndt Rolfs; Shoshana Revel-Vilk
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 5.  Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.

Authors:  Pilar Giraldo; Marcio Andrade-Campos
Journal:  J Blood Med       Date:  2021-12-07

6.  Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.

Authors:  Barry E Rosenbloom; Maria Domenica Cappellini; Neal J Weinreb; Marta Dragosky; Shoshana Revel-Vilk; Julie L Batista; Davorka Sekulic; Pramod K Mistry
Journal:  Am J Hematol       Date:  2022-08-24       Impact factor: 13.265

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.